Home » Stocks » RIGL

Rigel Pharmaceuticals, Inc. (RIGL)

Stock Price: $3.11 USD 0.18 (6.14%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $3.10 -0.01 (-0.32%) Nov 27, 4:40 PM

Stock Price Chart

Key Info

Market Cap 525.53M
Revenue (ttm) 105.57M
Net Income (ttm) -27.71M
Shares Out 168.98M
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $3.11
Previous Close $2.93
Change ($) 0.18
Change (%) 6.14%
Day's Open 2.96
Day's Range 2.90 - 3.16
Day's Volume 1,721,603
52-Week Range 1.23 - 5.24

More Stats

Market Cap 525.53M
Enterprise Value 493.82M
Earnings Date (est) Mar 9, 2021
Ex-Dividend Date n/a
Shares Outstanding 168.98M
Float 168.48M
EPS (basic) -0.15
EPS (diluted) -0.17
FCF / Share -0.28
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 23.46M
Short Ratio 9.26
Short % of Float 13.93%
Beta 1.41
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.98
PB Ratio 9.72
Revenue 105.57M
Operating Income -27.48M
Net Income -27.71M
Free Cash Flow -47.63M
Net Cash 31.71M
Net Cash / Share 0.19
Gross Margin 5.21%
Operating Margin -26.03%
Profit Margin -26.20%
FCF Margin -45.12%
ROA -12.31%
ROE -46.23%
ROIC -25.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (7)

Buy 6
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$7.33*
(135.69% upside)
Low
5.00
Current: $3.11
High
8.00
Target: 7.33
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue59.2944.514.4820.3828.908.257.152.254.75125
Revenue Growth33.2%892.62%-78%-29.46%250.24%15.38%217.78%-52.63%-96.2%-
Gross Profit58.3844.224.4820.3828.908.257.152.254.75125
Operating Income-69.09-72.68-78.88-69.65-51.69-91.15-89.45-99.36-86.3735.32
Net Income-66.89-70.48-77.99-69.22-51.46-90.91-89.03-98.84-85.9737.89
Shares Outstanding16716112694.3988.4387.6687.2974.9763.3352.06
Earnings Per Share-0.40-0.44-0.62-0.73-0.58-1.04-1.02-1.32-1.360.72
Operating Cash Flow-41.51-58.83-77.56-75.89-23.41-69.75-86.08-85.21-69.3846.74
Capital Expenditures-1.46-1.110.57-0.72-0.49-0.18-1.21-3.36-2.30-3.56
Free Cash Flow-42.97-59.93-76.99-76.61-23.90-69.93-87.28-88.57-71.6843.18
Cash & Equivalents98.0812911674.77126143212298248177
Total Debt36.31--------0.80
Net Cash / Debt61.7712911674.77126143212298248176
Assets14813911978.13132154226310257187
Liabilities93.7529.2318.4723.1140.3725.8917.8120.9520.9620.56
Book Value53.8211010155.0391.38128208289236166
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Rigel Pharmaceuticals, Inc.
Country United States
Employees 163
CEO Raul R. Rodriguez

Stock Information

Ticker Symbol RIGL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RIGL
IPO Date November 29, 2000

Description

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trials for warm autoimmune hemolytic anemia; R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trials for autoimmune and inflammatory diseases; and R552, a receptor-interacting protein kinase Inhibitor that is in phase I clinical trials for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Company to develop and commercialize Fostamatinib. Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.